EACTA SURVEY ON TRANSFUSION POLICY IN EUROPEAN
CARDIAC SURGERY INSTITUTIONS
This survey is endorsed by EACTA and funded by an unrestricted educational grant from Novo
Nordisk A/S. The results of this survey will be presented at the next EACTA Annual Meeting in
Athens, May 2009, and may be used for scientific publications in peer-reviewed journals.
Please fill out the form and e-mail it back to: cardioanestesia@virgilio.it as an attachment.
It is not mandatory to fill out all the items. Please provide us with the level of information that you
actually have.
Data should refer to ADULT cardiac surgery only.
This survey is intended to reflect the transfusion policy in your Institution. Quantitative data
should reflect one year of activity, preferably 2008, but if data are not yet available, 2007.
Do not combine data from different periods of time.
______________________________________________________________________________
Session I - Identification
Institution…………………………………………………………………………………………….
City ………………………………………………………………………………………………….
Country ………………………………………………………………………………………………
Number of cardiac surgery interventions in 2008 or 2007………
_______________________________________________________________________________
Session II – Operation characteristics
Isolated CABG …………..
Isolated valve ……………
CABG + valve (1 or 2) ……………
Double/triple valve ………………..
Ascending aorta …………………..
Number of off-pump procedures………
Number of redo operations ……………
Elective procedures ………………
Urgent procedures (to be performed within 24 hours) …………..
Emergency procedures (to be performed immediately) …………
Salvage procedures (patient under cardiac massage or similar) ……….
________________________________________________________________________________
________________________________________________________________________________
Session III – Patients details
Insert absolute numbers in the dashed lines
Gender male ………….
Age ≥ 65 years …………
BSA ≤ 1.9 m2 ………….
Hematocrit < 35% ……..
Diabetes on medication …………
Serum creatinine > 1.25 mg/dL …………
Chronic dialytic treatment ………………
________________________________________________________________________________
Session IV – Preoperative medications
Insert absolute numbers in the dashed lines
Salycilates in the 7 days before the operation ………………….
Tyenopiridines (clopidogrel or ticlopidine) in the 7 days before the operation ………….
Oral anticoagulants (warfarin – coumadin) not discontinued ………………
GPIIb/IIIa inhibitors active at the moment of the operation ……………….
Subcutaneous LMWH until the operation day …………………….
Intravenous heparin until the operation day ………………………
________________________________________________________________________________
Session V – Hemostatic drugs used during or after the operation
Insert absolute numbers in the dashed lines
Aprotinin ………..
Tranexamic acid ……….
Epsilon-aminocaproic acid …………..
Desmopressin ……………………….
Recombinant activated factor VII …………
________________________________________________________________________________
________________________________________________________________________________
Session VI – Packed red cells (PRCs) transfusions
________________________________________________________________________________
Number of patients receiving PRCs ………………
Number receiving 1 –2 units ……………………..
Number receiving 3 – 4 units …………………….
Number receiving > 4 units ………………………
Number being transfused during the operation ……………
Number being transfused after the operation …………….
________________________________________________________________________________
Session VII – Fresh frozen plasma (FFP) transfusions
________________________________________________________________________________
Number of patients receiving FFP ………………
Number receiving 1 –2 units ……………………..
Number receiving 3 – 4 units …………………….
Number receiving > 4 units ………………………
Number being transfused during the operation ……………
Number being transfused after the operation …………….
________________________________________________________________________________
Session VIII – Platelets (PLTs) transfusions
________________________________________________________________________________
Number of patients receiving PLTs ………………
Number receiving 1 unit ……………………..
Number receiving 2 units …………………….
Number receiving > 2 units ………………………
Number being transfused during the operation ……………
Number being transfused after the operation …………….
________________________________________________________________________________
Session IX
________________________________________________________________________________
Number receiving cryoprecipitates ……………..
________________________________________________________________________________
________________________________________________________________________________
Session X – Postoperative complications
________________________________________________________________________________
Number of re-explorations due to bleeding …………..
Acute renal failure (creatinine > 2.0 mg/dL AND > baseline value x 2) …………..
Acute renal failure requiring renal replacement therapy …………………..
Thromboembolic events (stroke, myocardial infarction, peripheral thromboembolism, pulmonary
embolism, mesenteric infarction) ……………..
________________________________________________________________________________
Session XI – Transfusion policy
________________________________________________________________________________
Indicate the trigger value of hemoglobin (hematocrit/3) at which PRCs are transfused in the
following different scenarios
________________________________________________________________________________
DURING CARDIOPULMONARY BYPASS
Age of the patient < 65 years
Trigger value of Hb for transfusions ……………….
Age of the patient 66-75 years
Trigger value of Hb for transfusions ……………….
Age of the patient > 75 years
Trigger value of Hb for transfusions ……………….
________________________________________________________________________________
AFTER CARDIOPULMONARY BYPASS, DURING THE OPERATION
Patient male, < 65 years , no major inotropic support
Trigger value of Hb ……………….
Patient male, ≥ 65 years , no major inotropic support
Trigger value of Hb ……………….
Patient male, < 65 years , with major inotropic support
Trigger value of Hb ……………….
Patient male, ≥ 65 years , with major inotropic support
Trigger value of Hb ……………….
Patient female, < 65 years , no major inotropic support
Trigger value of Hb ……………….
Patient female, ≥ 65 years , no major inotropic support
Trigger value of Hb ……………….
Patient female, < 65 years , with major inotropic support
Trigger value of Hb ……………….
Patient female, ≥ 65 years , with major inotropic support
Trigger value of Hb ……………….
________________________________________________________________________________
DURING THE ICU STAY
Patient male, < 65 years , no major inotropic support
Trigger value of Hb ……………….
Patient male, ≥ 65 years , no major inotropic support
Trigger value of Hb ……………….
Patient male, < 65 years , with major inotropic support
Trigger value of Hb ……………….
Patient male, ≥ 65 years , with major inotropic support
Trigger value of Hb ……………….
Patient female, < 65 years , no major inotropic support
Trigger value of Hb ……………….
Patient female, ≥ 65 years , no major inotropic support
Trigger value of Hb ……………….
Patient female, < 65 years , with major inotropic support
Trigger value of Hb ……………….
Patient female, ≥ 65 years , with major inotropic support
Trigger value of Hb ……………….
________________________________________________________________________________
THANK YOU !